Important Safety Information
Prescribing Information

Kloxxado
  • What is KLOXXADO®
    • Why KLOXXADO®
    • How to Use KLOXXADO®
    • How to Get KLOXXADO®
  • Health Professionals
    • Physicians & Prescribers
    • Pharmacists
    • Healthcare Resources
    • Healthcare FAQs
  • Community Groups
    • Community Organizations
    • Law Enforcement
    • Community Resources
    • Community FAQs
  • Resources
    • Accidental Overdose
    • The Opioid Epidemic
    • Facts About Fentanyl
  • FAQs
  • Blog

       Naloxone Blog


      Welcome to the KLOXXADO® Naloxone Blog

      Find the latest news about KLOXXADO® (naloxone HCl) Nasal Spray 8 mg, as well as helpful information about opioid overdose safety, opioid addiction treatment and recovery. Check back often to see our latest blog posts.

      Editor

      Co-Prescribing KLOXXADO® (naloxone HCI) nasal spray 8 mg for Your Patients Taking Prescription Opioids - Kloxxado®

      It’s estimated that five to eight million Americans use opioids to manage chronic pain (i.e., pain lasting longer than three months).1,2 Opioids are also used for acute pain, cancer-related pain,…
      Tags: Healthcare Professionals, Community Groups, Patients & Caregivers
      Read More

      Opioids on Campus? Be Ready With KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

      Tags: Opioid Awareness, Kloxxado, Opioid Overdose, Counterfeit Pills
      Read More

      The Importance of Naloxone for Older Adults on Medications

      Did you know that more than half of adults aged 65 and older take 4 or more prescription drugs? For many, it’s because they’re managing conditions like high blood pressure, diabetes and/or arthritis.…
      Tags: News, Community Groups, Opioid Safety, Patients & Caregivers, Opioid Overdose, Counterfeit Pills
      Read More

      KLOXXADO® (naloxone HCl) Nasal Spray 8 mg Shelf-Life Extended from 24 months to 36 months

      The FDA has recently announced the approval of the shelf-life extension of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg from 24 to 36 months from date of manufacture. KLOXXADO® packaging has been…
      Tags: News, Healthcare Professionals, Community Groups, Patients & Caregivers
      Read More

      Naloxone: What is Naloxone and How Does It Work

      The science behind naloxone Drug overdose is the leading cause of unintentional death in the US, and most of these overdoses involve opioids. Naloxone is a life-saving medicine that can be used to…
      Tags: News, Healthcare Professionals, Community Groups, Patients & Caregivers
      Read More

      US FDA Approves KLOXXADO® (naloxone HCl) Nasal Spray 8 mg to Treat Opioid Overdose

      On April 30, 2021, the US Food and Drug Administration approved of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg, a new opioid overdose reversal medication. Naloxone, the key medicine in KLOXXADO®, has a…
      Tags: News, Healthcare Professionals, Community Groups, Patients & Caregivers
      Read More

        Topics

        • Community Groups (5)
        • Patients & Caregivers (5)
        • Healthcare Professionals (4)
        • News (4)
        • Counterfeit Pills (2)

        Archives

        • February 2026 (2)
        • October 2021 (1)
        • March 2024 (1)
        • August 2024 (1)
        • January 2025 (1)

        Important Safety Information and Indication for KLOXXADO® (naloxone HCl) NASAL SPRAY 8 mg

        What is the most important information I should know about KLOXXADO® Nasal Spray?

        Get emergency medical help right away after giving the first dose of KLOXXADO® Nasal Spray. The signs and symptoms of an opioid emergency can return after KLOXXADO® Nasal Spray is given. If this happens, give another dose after 2 to 3 minutes using a new KLOXXADO® Nasal Spray and watch the person closely until emergency help is received.

        Read More...

        Important Safety Information and Indication for KLOXXADO® (naloxone HCl) NASAL SPRAY 8 mg

        What is KLOXXADO® Nasal Spray?

        • KLOXXADO® Nasal Spray is a prescription medicine used for the treatment of an opioid emergency such as an overdose or a possible opioid overdose in adults and children with signs of breathing problems and severe sleepiness or not being able to respond.
        • KLOXXADO® Nasal Spray is to be given right away and does not take the place of emergency medical care.
        • Get emergency medical help right away after giving the first dose of KLOXXADO® Nasal Spray, even if the person wakes up.

        What is the most important information I should know about KLOXXADO® Nasal Spray?

        Get emergency medical help right away after giving the first dose of KLOXXADO® Nasal Spray. The signs and symptoms of an opioid emergency can return after KLOXXADO® Nasal Spray is given. If this happens, give another dose after 2 to 3 minutes using a new KLOXXADO® Nasal Spray and watch the person closely until emergency help is received.

        The medicine in KLOXXADO® Nasal Spray is safe to use in people who are not taking opioids. KLOXXADO® Nasal Spray is not intended for self-administration.

        What should I tell my healthcare provider (pharmacist or prescriber) before using?

        Before using KLOXXADO® Nasal Spray, tell your healthcare provider about all of your medical conditions, including if you:

        • have heart problems
        • are pregnant or plan to become pregnant. Use of KLOXXADO® Nasal Spray may cause withdrawal symptoms in your unborn baby. Your unborn baby should be examined by a healthcare provider right away after you use KLOXXADO® Nasal Spray.
        • are breastfeeding or plan to breastfeed. It is not known if KLOXXADO® Nasal Spray passes into your breast milk.

        What are the possible serious side effects of KLOXXADO® Nasal Spray?

        KLOXXADO® Nasal Spray may cause sudden opioid withdrawal symptoms including body aches, diarrhea, increased heart rate, fever, runny nose, sneezing, goose bumps, sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, stomach cramping, weakness, and increased blood pressure.

        In infants under 4 weeks old who have been receiving opioids regularly, sudden opioid withdrawal may be life-threatening if not treated the right way. Signs and symptoms include seizures, crying more than usual, and increased reflexes.

        Who should not use KLOXXADO® Nasal Spray?

        Do not use KLOXXADO® Nasal Spray if you are allergic to naloxone hydrochloride or any of the ingredients in KLOXXADO® Nasal Spray.

        What are the most common side effects of KLOXXADO® nasal spray?

        The most common side effects of KLOXXADO® Nasal Spray in adults include stomach-area (abdomen) pain, weakness, dizziness, headache, nose (nasal) discomfort, and a feeling like you are going to faint.

        These are not all of the possible side effects of KLOXXADO® Nasal Spray. Please click here for the accompanying full Prescribing Information, including Patient Information, which includes a more complete discussion of the risks associated with KLOXXADO® Nasal Spray. Always contact your healthcare provider (pharmacist or prescriber) if you have questions or experience any side effects.

        You are encouraged to report negative side effects to the FDA at: 1-800-FDA-1088 or www.fda.gov/medwatch. You can also contact Hikma Specialty USA Inc. at: us.hikma@primevigilance.com or call 1-877-845-0689 or 1-800-962-8364.

        • About Emergent
        • Newsroom
        • Contact

        Tell Us About a Side Effect
        1-877-845-0689 or 1-800-962-8364  |  Email

        Contact Customer Service
        1-844-462-7226  |  Email

        This website is intended for U.S. audiences

        ©2026 Hikma Pharmaceuticals USA Inc. All rights reserved.

        • Privacy Policy
        • Sitemap
        Emergent BioSolutions

        KLOXXADO®️ is a registered trademark of Hikma Pharmaceuticals USA Inc.
        Emergent Devices Inc. is wholly owned subsidiary of Emergent BioSolutions Inc.
        KLOXXADO®️ is manufactured by Hikma Pharmaceuticals USA Inc. Columbus, OH 43228, and distributed by Emergent Devices Inc. Plymouth Meeting, PA 19462.

        Hikma

        PP-KLOX-US-00040

        February 2026